Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

References
1 Rosenberg, S. A. A new era for cancer
immunotherapy based on the genes
that encode cancer antigens, Immunity
10: 281±7, 1999.
2 Rosenberg, S. A. Progress in human
tumour immunology and immunotherapy,
Nature 411: 380±4, 2001.
3 Alyea, E. Adoptive immunotherapy: -
insights from donor lymphocyte
infusions, Transfusion 40: 393±5,
2000.
4 Heslop, H. E. and Rooney, C. M. Adoptive
cellular immunotherapy for EBV
lymphoproliferative disease, Immunol
Rev 157: 217±22, 1997.
5 Walter, E. A., Greenberg, P. D., Gilbert,
M. J., Finch, R. J.,Watanabe,
K. S., Thomas, E. D. and Riddell, S. R.
Reconstitution of cellular immunity
against cytomegalovirus in recipients of
allogeneic bone marrow by transfer of
T-cell clones from the donor, N Engl J
Med 333: 1038±44, 1995.
6 Yee, C., Thompson, J. A., Roche, P.,
Byrd, D. R., Lee, P. P., Piepkorn, M.,
Kenyon, K., Davis, M. M., Riddell,
S. R. and Greenberg, P. D. Melanocyte
destruction after antigen-specific immunotherapy
of melanoma: direct evidence
of T cell-mediated vitiligo, JExp
Med 192: 1637±44, 2000.
7 Schultze, J. L., Anderson, K. C., Gilleece,
M. H., Gribben, J. G. and Nadler,
L. M. A pilot study of combined immunotherapy
with autologous adoptive
tumour-specific T-cell transfer, vaccination
with CD40-activated malignant B
cells and interleukin 2, Br JHaematol
113: 455±60, 2001.
8 Rosenberg, S. A.,Yang, J. C.,
Schwartzentruber, D. J., Hwu, P.,
Marincola, F. M., Topalian, S. L., Restifo,
N. P., Dudley, M. E., Schwarz,
S. L., Spiess, P. J.,Wunderlich, J. R.,
Parkhurst, M. R., Kawakami,Y.,
Seipp, C. A., Einhorn, J. H. and
White, D. E. Immunologic and therapeutic
evaluation of a synthetic peptide
vaccine for the treatment of patients
with metastatic melanoma, Nat Med 4:
321±7, 1998.
References
9 Nestle, F. O., Alijagic, S., Gilliet, M.,
Sun,Y., Grabbe, S., Dummer, R.,
Burg, G. and Schadendorf, D. Vaccination
of melanoma patients with peptide-
or tumor lysate-pulsed dendritic
cells, Nat Med 4: 328±32, 1998.
10 Hsu, F. J., Benike, C., Fagnoni, F.,
Liles, T. M., Czerwinski, D., Taidi, B.,
Engleman, E. G. and Levy, R. Vaccination
of patients with B-cell lymphoma
using autologous antigen-pulsed dendritic
cells, Nat Med 2: 52±8, 1996.
11 Simon, R. M., Steinberg, S. M., Hamilton,
M., Hildesheim, A., Khleif,
S., Kwak, L. W., Mackall, C. L.,
Schlom, J., Topalian, S. L. and Berzofsky,
J. A. Clinical trial designs for
the early clinical development of therapeutic
cancer vaccines, JClin Oncol 19:
1848±54, 2001.
12 Van Pel, A., van der Bruggen, P.,
Coulie, P. G., Brichard,V. G.,
Lethe, B., van den Eynde, B., Uyttenhove,
C., Renauld, J. C. and Boon, T.
Genes coding for tumor antigens recognized
by cytolytic T lymphocytes, Immunol
Rev 145: 229±50, 1995.
13 Rosenberg, S. A. Cancer vaccines
based on the identification of genes encoding
cancer regression antigens, Immunol
Today 18: 175±82, 1997.
14 Van den Eynde, B. J. and van der Bruggen,
P. Tcell defined tumor antigens,
Curr Opin Immunol 9: 684±93, 1997.
15 Boon, T., Cerottini, J. C.,Van den
Eynde, B., van der Bruggen, P. and
Van Pel, A. Tumor antigens recognized
by T lymphocytes, Annu Rev Immunol
12: 337±65, 1994.
16 Sahin, U., Tureci, O. and
Pfreundschuh, M. Serological identification
of human tumor antigens, Curr
Opin Immunol 9: 709±16, 1997.
17 Gilboa, E. The makings of a tumor rejection
antigen, Immunity 11: 263±70,
1999.
18 Schultze, J. L. and Vonderheide,
R. H. From cancer genomics to cancer
immunotherapy: toward second-generation
tumor antigens, Trends Immunol
22: 516±23, 2001.
13